Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Cardiotoxicity 5Lymphoma 3Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neuroblastoma 1Localized Extraskeletal Ewing Sarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Inflammatory Breast Neoplasms 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

dinutuximab 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3Carboplatin 3Biopsy 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Irinotecan 2Etoposide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1etoposide phosphate 1Watchful Waiting 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Observation 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ganglioneuroblastoma × Razoxane × Clear all
NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡